Life Sciences

Wayne State Wins $7.5 million NIH Renewal For Environmental Center

DETROIT – Wayne State University received notice from the National Institute of Environmental Health Sciences of the National Institutes of Health has renewed a five-year, $7.5 million grant for the Center for Urban Responses to Environmental Stressors. The previous NIH grant for CURES totaled $2.4 million for three years. CURES — one of 22 P30

By |2017-05-03T10:49:01-04:00May 2nd, 2017|Life Sciences|

U-M Names Bipolar Disorder Research Program For Auto Entrepreneur Heinz Prechter

ANN ARBOR - The University of Michigan has named its bipolar disorder research program for Heinz Prechter, in honor of a new gift commitment of up to $5 million by the World Heritage Foundation - Prechter Family Fund. But the gift comes with a challenge to others who care about bipolar disorder: The Prechter family

By |2017-05-02T17:37:23-04:00May 2nd, 2017|Life Sciences|

Genomenon Gets $1.8 Million Grant From NIH To Fund Genomic Analysis

ANN ARBOR - Genomenon announced a $1.8 milion grant awarded by the National Institutes of Health will fund Genomenon’s further innovation in genomic analysis, streamlining the literature research and curation process leading to faster patient diagnosis. “This grant recognizes the solid approach and great potential of Genomenon’s technology to drive rapid improvements in automating accurate gene

By |2017-04-26T20:40:36-04:00April 26th, 2017|Life Sciences|

Enzo Life Sciences Introduces Innovative Ultra-Sensitive Multiplex IHC Kit

ANN ARBOR - Enzo Life Sciences has released its newest immunohistochemistry product, MULTIVIEW® PLUS (mouse-HRP/rabbit-AP) IHC Kit (Brown/Green). This non-biotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed paraffin-embedded tissues. The new MULTIVIEW PLUS IHC kit optimizes your IHC process by including the entire workflow, from antigen retrieval to

By |2017-04-21T12:00:43-04:00April 21st, 2017|Life Sciences|

ONL Therapeutics Adds Executives To Board, Management Team

  ANN ARBOR - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, Tuesday announced new appointments and promotions involving the company’s board of directors and management team. The company has appointed Christine (Chris) Gibbons as a new, independent member of its board of directors, replacing departing

By |2017-03-29T12:34:21-04:00March 29th, 2017|Life Sciences|

Researchers Focus On Cell Membranes To Develop Alzheimer’s Treatments

ANN ARBOR - Thin parts of the cell membranes of neurons turn out to be particularly vulnerable to a protein that collects in the brain of people with Alzheimer's disease, according to a University of Michigan researcher. The discovery could open an avenue for developing treatments for Alzheimer's disease that work within the cell's membrane.

By |2017-03-23T15:07:03-04:00March 23rd, 2017|Life Sciences|

U-M Health Science Resource Center Gets $11.7 Million NIH Award

ANN ARBOR - A new interdisciplinary health sciences resource center at the University of Michigan has received an $11.7 million award from the National Institutes of Health to advance regenerative medicine. The center, led by the School of Dentistry, brings together scientists, engineers and clinicians from several U-M departments in collaboration with researchers at the

By |2017-03-15T19:11:01-04:00March 15th, 2017|Life Sciences|

Gemphire Therapeutics Closes $12.5 Million Stock Sale, Announces Net Losses

ANN ARBOR - Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that it has closed on the sale of 1.3 million shares of stock to a select group of accredited investors that will raise about $12.5 million, providing cash flow through 2018.  Gemphire Therapeutics will use the money to fund development costs, the company said

By |2017-03-15T18:27:15-04:00March 15th, 2017|Life Sciences|

U-M Startup HistoSonics Raises $8.3 Million

ANN ARBOR - A University of Michigan startup that's developing a non-invasive way to remove diseased tissue from cancer patients using high-intensity ultrasound has attracted $8.3 million in Series B financing. The investment will help advance clinical trials of HistoSonics' Robotic Assisted Sonic Therapy—an innovative tissue-destruction technology targeted for liver cancer and other solid tumor

By |2017-03-15T16:48:43-04:00March 15th, 2017|Featured, Life Sciences|